Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma

• Published in: BMC cancer 2020-10, Vol.20 (1), p.1035-1035, Article 1035
• Main Authors: Liu, Wenshuai, Tong, Hanxing, Zhang, Chenlu, Zhuang, Rongyuan, Guo, He, Lv, Chentao, Yang, Hua, Lin, Qiaowei, Guo, Xi, Wang, Zhiming, Wang, Yan, Shen, Feng, Wang, Shengzhou, Dai, Chun, Wang, Guan, Liu, Jun, Lu, Weiqi, Zhang, Yong, Zhou, Yuhong
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Biomarkers, Tumor - genetics; Cancer therapies; Care and treatment; Cell Differentiation; Chromosome 12; Copy number; Cyclin-dependent kinase 4; Deoxyribonucleic acid; Development and progression; DNA; Endothelial cells; Female; Fibroblasts; Follow-Up Studies; Gene Amplification; Gene deletion; Gene expression; Gene Expression Regulation, Neoplastic; Gene fusion; Gene mutation; Gene rearrangement; Gene regulation; Genetic analysis; Genetic aspects; Genetic diversity; Genomes; Genomics - methods; Health aspects; Humans; Immune infiltration; Leiomyosarcoma; Leiomyosarcoma - genetics; Leiomyosarcoma - pathology; Liposarcoma; Liposarcoma - genetics; Liposarcoma - pathology; Male; MDM2 protein; Medical diagnosis; Metastases; Middle Aged; Mutation; p53 Protein; Polymerase chain reaction; Prognosis; PTEN protein; Ribonucleic acid; RNA; RNA-Seq; Soft tissue sarcoma; Software; Statistical analysis; Transcription (Genetics); Transcriptome; Tumor microenvironment; Whole Exome Sequencing; Young Adult
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-020-07456-2

Treating patients with advanced sarcomas is challenging due to great histologic diversity among its subtypes. Leiomyosarcoma (LMS) and de-differentiated liposarcoma (DDLPS) are two common and aggressive subtypes of soft tissue sarcoma (STS). They differ significantly in histology and clinical behaviors. However, the molecular driving force behind the difference is unclear. We collected 20 LMS and 12 DDLPS samples and performed whole exome sequencing (WES) to obtain their somatic mutation profiles. We also performed RNA-Seq to analyze the transcriptomes of 8 each of the LMS and DDLPS samples and obtained information about differential gene expression, pathway enrichment, immune cell infiltration in tumor microenvironment, and chromosomal rearrangement including gene fusions. Selected gene fusion events from the RNA-seq prediction were checked by RT-PCR in tandem with Sanger sequencing. We detected loss of function mutation and deletion of tumor suppressors mostly in LMS, and oncogene amplification mostly in DDLPS. A focal amplification affecting chromosome 12q13-15 region which encodes MDM2, CDK4 and HMGA2 is notable in DDLPS. Mutations in TP53, ATRX, PTEN, and RB1 are identified in LMS but not DDLPS, while mutation of HERC2 is only identified in DDLPS but not LMS. RNA-seq revealed overexpression of MDM2, CDK4 and HMGA2 in DDLPS and down-regulation of TP53 and RB1 in LMS. It also detected more fusion events in DDLPS than LMS (4.5 vs. 1, p = 0.0195), and the ones involving chromosome 12 in DDLPS stand out. RT-PCR and Sanger sequencing verified the majority of the fusion events in DDLPS but only one event in LMS selected to be tested. The tumor microenvironmental signatures are highly correlated with histologic types. DDLPS has more endothelial cells and fibroblasts content than LMS. Our analysis revealed different recurrent genetic variations in LMS and DDLPS including simultaneous upregulation of gene expression and gene copy number amplification of MDM2 and CDK4. Up-regulation of tumor related genes is favored in DDLPS, while loss of suppressor function is favored in LMS. DDLPS harbors more frequent fusion events which can generate neoepitopes and potentially targeted by personalized immune treatment.